SCHEMBL2851368

SCHEMBL2851368

O=C(O[C@H]1CN2CCC1CC2)c1n[nH]c2cc(OC(F)F)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.45
HTR3A P46098 2/20 0.45
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
CHRNB2 P17787 1/20 0.45
CHRNA4 P43681 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
GLA P06280 1/20 0.42
TSHR P16473 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GSK3B P49841 4/20 0.39
DYRK1A Q13627 4/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851370 1.00 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
Formic Acid SCHEMBL2858552 0.96 CHRNA7 (0.42) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL2862498 0.92 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL13528909 0.92 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL2853813 0.92 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL2853772 0.90 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL2854411 0.90 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL13528907 0.90 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
SCHEMBL2854181 0.90 CHRNA7 (0.45) CHRNA7HTR3AHTR3EHTR3BCHRNB2
Formic Acid SCHEMBL2858715 0.89 CHRNA7 (0.42) CHRNA7HTR3AHTR3EHTR3BCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828179-B1 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES MEMORY PHARM CORP (US) 2010-01-20 EP claimed
US-7625924-B2 Nicotinic alpha-7 receptor ligands and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2009-12-01 US claimed
US-20060167039-A1 Nicotinic alpha-7 receptor ligands and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION 2006-07-27 US claimed
EP-2247312-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN Genentech, Inc. (US) 2010-11-10 EP disclosed
EP-2247620-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE Genentech, Inc. (US) 2010-11-10 EP disclosed
EP-2176296-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE Genetech, Inc. (US) 2010-04-21 EP disclosed
US-20100016351-A1 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF NGUYEN TRUC MINH 2010-01-21 US disclosed
US-20100016351-A1 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF NGUYEN TRUC MINH 2010-01-21 US disclosed
US-20100016351-A1 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF NGUYEN TRUC MINH 2010-01-21 US disclosed
EP-1828179-B1 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES MEMORY PHARM CORP (US) 2010-01-20 EP disclosed
US-7625924-B2 Nicotinic alpha-7 receptor ligands and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2009-12-01 US disclosed
US-7625924-B2 Nicotinic alpha-7 receptor ligands and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2009-12-01 US disclosed
US-7625924-B2 Nicotinic alpha-7 receptor ligands and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2009-12-01 US disclosed
WO-2009099719-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN GENENTECH, INC. (US) 2009-08-13 WO disclosed
WO-2009099728-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2009-08-13 WO disclosed
WO-2009012268-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2009-01-22 WO disclosed
EP-1828179-A2 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF Memory Pharmaceutical Corporation (US) 2007-09-05 EP disclosed
US-20060167039-A1 Nicotinic alpha-7 receptor ligands and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION 2006-07-27 US disclosed
WO-2006069097-A2 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167039-A1 Nicotinic alpha-7 receptor ligands and preparation and uses thereof CHRNA7, CHRNA5, CHRNA6 CHRNA7 1/4885HTR3A 352/4885HTR3E 628/4885
US-20100016351-A1 NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF CHRNA7, CHRNA5, CHRNA6 CHRNA7 1/4885HTR3A 352/4885HTR3E 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.